In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Ocugen (OCGN – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $2.16, close to its 52-week low of $2.10.
According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 9.6% and a 28.2% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Ayala Pharmaceuticals, and Onconova Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ocugen with a $8.13 average price target.
See today’s best-performing stocks on TipRanks >>
Ocugen’s market cap is currently $465.8M and has a P/E ratio of -7.25.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
